AbbVie (ABBV) Issues Long-Term Outlook; Boosts Qtr. Dividend

Go back to AbbVie (ABBV) Issues Long-Term Outlook; Boosts Qtr. Dividend

UBS Reiterates Buy on AbbVie (ABBV) Following Conference Call

November 2, 2015 9:58 AM EST

UBS reiterated a Buy rating and $78.00 price target on Abbvie (NYSE: ABBV) following the company's conference call. Management assumes no biosimiliars before 2022, and low mid-single digit annual price increases. On Humira biosimilar, management believes US biosimilars will likely infringe its dosing patents as they have to demonstrate efficacy at equal dosing.

Analyst... More

AbbVie (ABBV) Reports Strong 3Q and Long term outlook; Cowen Reiterates Outperform

October 30, 2015 1:23 PM EDT

Cowen reiterated an Outperform rating and $77.00 price target on Abbvie (NYSE: ABBV) following the company's 3Q earnings results. Q3 EPS of $1.13 was $0.06 above consensus. Full year guidance has been raised to $4.26-4.28 (prior $4.10-4.30). Q3 sales of $5,944MM (+18%) were $54MM above... More

AbbVie (ABBV) Raises Quarterly Dividend 11.8% to $0.57; 4.2% Yield

October 30, 2015 6:57 AM EDT

AbbVie (NYSE: ABBV) declared a quarterly dividend of $0.57 per share, or $2.28 annualized. This is an 11.8% increase from the prior dividend of $0.51.

The dividend will be payable on February 16, 2016, to stockholders of record on January 15, 2016, with an ex-dividend date of January 13,... More